Fresenius Kabi USA, LLC recalls DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only,
Recalled December 2, 2020 · FDA recall D-0105-2021 · Fresenius Kabi USA
Hazard
Cross Contamination with Other Products: trace amounts of octreotide found during testing · FDA Class III
Units
16,986 vials
Sold at
Nationwide USA and Puerto Rico
Description
Cross Contamination with Other Products: trace amounts of octreotide found during testing
Product
DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05
Manufacturer(s)
Fresenius Kabi USA, LLC
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →